Cargando…

Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test

The Centers for Disease Control and Prevention (CDC) and many public health jurisdictions continue to advocate for the most sensitive rapid HIV test that is available. Currently, the recommendation is to utilize tests that can detect HIV infection biomarkers within 30 days of infection, when initial...

Descripción completa

Detalles Bibliográficos
Autores principales: Guillon, Geraldine, Yearwood, Graham, Snipes, Casey, Boschi, Daniel, Reed, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834934/
https://www.ncbi.nlm.nih.gov/pubmed/29507828
http://dx.doi.org/10.7717/peerj.4430
_version_ 1783303740533506048
author Guillon, Geraldine
Yearwood, Graham
Snipes, Casey
Boschi, Daniel
Reed, Michael R.
author_facet Guillon, Geraldine
Yearwood, Graham
Snipes, Casey
Boschi, Daniel
Reed, Michael R.
author_sort Guillon, Geraldine
collection PubMed
description The Centers for Disease Control and Prevention (CDC) and many public health jurisdictions continue to advocate for the most sensitive rapid HIV test that is available. Currently, the recommendation is to utilize tests that can detect HIV infection biomarkers within 30 days of infection, when initial immune responses are mounted. The infected patient’s IgM response is often used to detect acute infection within a 20–25 days window after infection. This requirement applies to lab-based testing with automated analyzers and rapid, point of care (POC) testing used for screening in a non-clinical setting. A recent study has demonstrated that POC tests using a Protein A-based detection system can detect samples with predominantly HIV-1 IgM reactivity (Moshgabadi et al., 2015). The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test (OraQuick ADVANCE®) also uses Protein A as the detection protein in the antibody-binding colloidal gold conjugate, so it is expected that the OraQuick ADVANCE® Test will also detect samples with predominantly IgM reactivity. This report definitively demonstrates that the OraQuick ADVANCE® Test can detect IgM antibodies during an acute infection window period of approximately 20–25 days after infection, and is therefore suitable for use in testing environments requiring adherence to current CDC recommendations.
format Online
Article
Text
id pubmed-5834934
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-58349342018-03-05 Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test Guillon, Geraldine Yearwood, Graham Snipes, Casey Boschi, Daniel Reed, Michael R. PeerJ Biotechnology The Centers for Disease Control and Prevention (CDC) and many public health jurisdictions continue to advocate for the most sensitive rapid HIV test that is available. Currently, the recommendation is to utilize tests that can detect HIV infection biomarkers within 30 days of infection, when initial immune responses are mounted. The infected patient’s IgM response is often used to detect acute infection within a 20–25 days window after infection. This requirement applies to lab-based testing with automated analyzers and rapid, point of care (POC) testing used for screening in a non-clinical setting. A recent study has demonstrated that POC tests using a Protein A-based detection system can detect samples with predominantly HIV-1 IgM reactivity (Moshgabadi et al., 2015). The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test (OraQuick ADVANCE®) also uses Protein A as the detection protein in the antibody-binding colloidal gold conjugate, so it is expected that the OraQuick ADVANCE® Test will also detect samples with predominantly IgM reactivity. This report definitively demonstrates that the OraQuick ADVANCE® Test can detect IgM antibodies during an acute infection window period of approximately 20–25 days after infection, and is therefore suitable for use in testing environments requiring adherence to current CDC recommendations. PeerJ Inc. 2018-02-28 /pmc/articles/PMC5834934/ /pubmed/29507828 http://dx.doi.org/10.7717/peerj.4430 Text en © 2018 Guillon et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Biotechnology
Guillon, Geraldine
Yearwood, Graham
Snipes, Casey
Boschi, Daniel
Reed, Michael R.
Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test
title Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test
title_full Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test
title_fullStr Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test
title_full_unstemmed Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test
title_short Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test
title_sort human anti-hiv igm detection by the oraquick advance® rapid hiv 1/2 antibody test
topic Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834934/
https://www.ncbi.nlm.nih.gov/pubmed/29507828
http://dx.doi.org/10.7717/peerj.4430
work_keys_str_mv AT guillongeraldine humanantihivigmdetectionbytheoraquickadvancerapidhiv12antibodytest
AT yearwoodgraham humanantihivigmdetectionbytheoraquickadvancerapidhiv12antibodytest
AT snipescasey humanantihivigmdetectionbytheoraquickadvancerapidhiv12antibodytest
AT boschidaniel humanantihivigmdetectionbytheoraquickadvancerapidhiv12antibodytest
AT reedmichaelr humanantihivigmdetectionbytheoraquickadvancerapidhiv12antibodytest